Breast cancer 1, early onset
Locus: NM_007297
Definition: Homo sapiens breast cancer 1, early onset (BRCA1), transcript
variant BRCA1-delta2-10, mRNA.
Patent
| Patent number | Owner | issue date | Expiration date | Claims |
| US 5,622,829 | UC | Apr. 22, 1997 | cell-content | Isolated nucleic acid |
| US 5,654,155 | OncorMed | Aug. 5, 1997 | cell-content | Isolated DNA |
| US 5,693,473 | Myriad | Dec. 2, 1997 | cell-content | Isolated DNA comprising BRCA1 mutations |
| US 5,710,001 | Myriad; Univ. Utah; NIH | Jan. 20, 1998 | cell-content | Method for screening for BRCA1 alterations |
| US 5,747,282 | Myriad; Univ. Utah; NIH | May 5, 1998 | cell-content | Isolated DNA coding for BRCA1 |
Significance
BRCA-1 is linked to susceptibility for breast and ovarian cancer.
Licensing
The BRCA1 patents, US 5747282 and 5710001, provide Myriad with exclusive rights in the United States to commercial laboratory testing services and diagnostics kits that utilize the BRCA1 gene sequences. Myriad is now marketing the test, which costs $3,120, to the general public through print and television advertising (Pollack, “A Genetic Test That Very Few Need, Marketed to the Masses,” The New York Times, Feb. 11, 2007 (http://www.nytimes.com/2007/09/11/business/media/11genetics.html?_r=2&oref=slogin&oref=slogin)
